ABSTRACT
Objective Medication review (MR) is the systematic assessment of a patient’s medicines - a critical step in preventing of drug adverse events. MR aims to identify drug-related problems (DRP) that trigger documented pharmacist interventions (PI). The information-rich data documenting PI, produced daily, provides a unique opportunity to develop a deep learning algorithm to automatically categorize PI.
Materials and Methods The study was conducted at the University Hospital of Strasbourg. Text data documenting PI were collected over the year 2017. Data from the first six-months of 2017 were reviewed by pharmacists who manually assigned to each PI the main class of the 29 possible classes of the French Society of Clinical Pharmacy classification. A deep neural network classifier was then trained to learn to automatically predict the main PI class from processed text data. Accuracy, specificity and sensitivity metrics were used to evaluate performance.
Results 27,699 PI (first six-months of 2017) were extracted, processed and used to train and evaluate a classifier. Class prediction accuracy calculated on the validation dataset was 78.0%. Class specific sensitivities and specificities ranged from 0.31 to 0.96 and from 0.94 to 1.00, respectively. To demonstrate the classification ability of the algorithm, we predicted the PI class for documents collected during the second semester of 2017. Of the 4,460 predictions checked, only 67 required corrections. The latter data was concatenated with the original dataset to create an extended dataset to re-train the neural network. The updated global accuracy reached 81.0% showing that the prediction process can still improve with the increase in the amount of data.
Conclusion PI classification is beneficial for assessing and improving pharmaceutical care practice. Here we report a high performance automatic PI classification based on deep learning. This application could find an essential place to highlight the clinical relevance of the review of drug prescriptions performed daily by hospital pharmacists.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Comite d'ethique des Facultes de Medecine, d'Odontologie, de Pharmacie, des Ecoles d'Infirmieres, de Kinesitherapie, de Maieutique et des Hopitaux gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
